RNA °£¼· ±â¼ú ½ÃÀå : À¯Çüº°, Ä¡·áÁ¦º°, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)
RNA Interference Technology Market by Type (dsRNA, miRNA, siRNA), Therapeutics (Autoimmune Hepatitis, Hepatitis B and C, Neurological Disorders), Application - Global Forecast 2025-2030
»óǰÄÚµå : 1601251
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 191 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

RNA °£¼· ±â¼ú ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 329¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 392¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 22.38%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 1,354¾ï ´Þ·¯¿¡ ´ÞÇÑ´Ù°í ¿¹ÃøµË´Ï´Ù.

RNA °£¼·(RNAi) ±â¼úÀº ºÐÀÚ »ý¹°ÇÐÀÇ Çõ¸íÀûÀÎ µµ±¸·Î, ƯÁ¤ À¯ÀüÀÚÀÇ Ä§¹¬À» °¡´ÉÇÏ°Ô Çϰí, À¯ÀüÀÚ ±â´É ¿¬±¸ ¹× »õ·Î¿î Ä¡·á Àü·« °³¹ß¿¡ °­·ÂÇÑ ¼ö´ÜÀ» Á¦°øÇÕ´Ï´Ù. ±× ¹üÀ§´Â ±âÃÊ ¿¬±¸, â¾à, Ä¡·á¿¡ÀÇ ÀÀ¿ë µî ´Ù¹æ¸é ¹× ÁÖ·Î À¯Àü¼º Áúȯ°ú ÈÄõ¼º Áúȯ¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. RNAiÀÇ Çʿ伺Àº Áúº´ÀÇ ¿øÀÎÀÌ µÇ´Â À¯ÀüÀÚ¸¦ Á¤È®ÇÏ°Ô Ç¥ÀûÀ¸·Î ÇÏ´Â ±×°ÍÀÇ µ¶Æ¯ÇÑ ´É·Â¿¡ ÀÖ¾î, ÀÌ¿¡ ÀÇÇØ ¸ÂÃãÇü ÀǷᳪ, ¾Ï, ¹ÙÀÌ·¯½º °¨¿°Áõ, À¯Àü¼º Áúȯ µîÀÇ Ä¡·á¸¦ ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â Á¦¾àȸ»ç, »ý¸í°øÇбâ¾÷, Çмú¿¬±¸±â°ü µî ´Ù¾çÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 329¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 392¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 1,354¾ï ´Þ·¯
CAGR(%) 22.38%

RNAi ±â¼ú ½ÃÀå ¼ºÀåÀº ±â¼úÀÇ Áøº¸, ¸¸¼º Áúȯ Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÇ È®´ë·Î Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ RNAi R&D¿¡ ´ëÇÑ ¸¹Àº ÅõÀÚ¿Í Çмú±â°ü°ú »ý¸í°øÇбâ¾÷ÀÇ °øµ¿ ¿¬±¸°¡ Çõ½ÅÀÇ »õ·Î¿î ¹®À» ¿­°í ÀÖ½À´Ï´Ù. Àü´Þ ¹æ¹ýÀÇ ÃÖ±Ù µ¿Çâ°ú °­·ÂÇÏ°í ¼±ÅÃÀûÀÎ siRNAÀÇ °³¹ßÀº ÀÓ»ó ÀÀ¿ë¿¡¼­ Å« ±âȸ¸¦ Á¦½ÃÇÕ´Ï´Ù. ºÏ¹Ì´Â °ß°íÇÑ ÇコÄɾî ÀÎÇÁ¶ó¿Í ¿¬±¸È°µ¿À» ÅëÇØ ÇöÀç ¼±µµÇϰí ÀÖÁö¸¸, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÇコÄɾî ÅõÀÚ Áõ°¡¿Í À¯ÀüÀÚ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÚ±Ý Áõ°¡¿¡ ÀÇÇØ ´ëÆøÀûÀÎ ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

±×·¯³ª RNAi ºÐÀÚÀÇ ¼¼Æ÷Áú Àü´Þ °úÁ¦, ¿ÀÇÁŸ°Ù È¿°úÀÇ °¡´É¼º, »ý¹°ÇÐÀû ȯ°æ¿¡¼­ ¾ÈÁ¤¼º Çâ»óÀÇ Çʿ伺 µî ½ÃÀåÀº ¸î °¡Áö ÇѰ迡 Á÷¸éÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú ³ôÀº °³¹ß ºñ¿ëÀº ½ÃÀåÀÇ ¼ºÀå°ú º¸±Þ¿¡ ¿©ÀüÈ÷ Å« µµÀüÀÔ´Ï´Ù. Àü´Þ ½Ã½ºÅÛÀÇ °­È­, Ç¥Àû ƯÀ̼ºÀÇ °³¼±, º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ RNAi Àü´ÞÀ» À§ÇÑ ³ª³ëÀÔÀÚÀÇ À̿뿡 ÃÊÁ¡À» ¸ÂÃá Çõ½ÅÀº R&DÀÇ À¯¸Á ºÐ¾ßÀÔ´Ï´Ù. ±â¾÷Àº RNAi¿Í CRISPR°ú °°Àº ´Ù¸¥ À¯ÀüÀÚ ÆíÁý ±â¼ú°úÀÇ À¶ÇÕ¿¡ ÅõÀÚÇÏ¿© Ä¡·á ¿ëµµ¸¦ È®´ëÇϰí, Çмú ¿¬±¸ ±â°ü°úÀÇ Á¦ÈÞ¸¦ Ȱ¿ëÇÏ¿© ÀÌ ¿ªµ¿ÀûÀÎ ½ÃÀå¿¡¼­ÀÇ Çõ½Å°ú ä¿ëÀ» °¡¼ÓÈ­ ÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â RNA °£¼· ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

RNA °£¼· ±â¼ú ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces: RNA °£¼· ±â¼ú ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¹ýÀ» Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¼öÀÖ´Â ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : RNA °£¼· ±â¼ú ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº RNA °£¼· ±â¼ú ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À» ¿¹ÃøÇÏ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® RNA °£¼· ±â¼ú ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

RNA °£¼· ±â¼ú ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º RNA °£¼· ±â¼ú ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â RNA °£¼· ±â¼ú ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå RNA °£¼· ±â¼ú ½ÃÀå : À¯Çüº°

Á¦7Àå RNA °£¼· ±â¼ú ½ÃÀå : Ä¡·áº°

Á¦8Àå RNA °£¼· ±â¼ú ½ÃÀå : ¿ëµµº°

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ RNA °£¼· ±â¼ú ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ RNA °£¼· ±â¼ú ½ÃÀå

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ RNA °£¼· ±â¼ú ½ÃÀå

Á¦12Àå °æÀï ±¸µµ

¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The RNA Interference Technology Market was valued at USD 32.92 billion in 2023, expected to reach USD 39.25 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 135.40 billion by 2030.

RNA interference (RNAi) technology is a revolutionary tool in molecular biology that enables the silencing of specific genes, thus providing a powerful means for studying gene function and developing novel therapeutic strategies. Its scope extends across multiple dimensions, including basic research, drug discovery, and therapeutic application, primarily focusing on genetic and acquired diseases. The necessity of RNAi lies in its unique ability to precisely target disease-causing genes, thereby offering promise in personalized medicine and treatment of conditions like cancer, viral infections, and genetic disorders. The tight end-use scope involves pharmaceuticals, biotechnology companies, and academic research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 32.92 billion
Estimated Year [2024] USD 39.25 billion
Forecast Year [2030] USD 135.40 billion
CAGR (%) 22.38%

Market growth for RNAi technology is heavily influenced by technological advancements, increasing incidences of chronic diseases, and the expanding interest in personalized medicine. Additionally, substantial investments in RNAi research and development, along with collaborations between academic institutions and biotech firms, are opening new doors for innovation. Recent advancements in delivery methods and the development of potent and selective siRNAs present significant opportunities in clinical applications. The North American region is currently leading due to robust healthcare infrastructure and research activity, yet Asia-Pacific is expected to witness substantial growth due to rising healthcare investments and increased government funding for genetic research.

However, the market faces several limitations, such as delivery challenges of RNAi molecules into the cell cytoplasm, potential off-target effects, and the necessity for improved stability in biological settings. Furthermore, regulatory hurdles and high development costs remain significant challenges to market growth and widespread adoption. Innovations focusing on enhanced delivery systems, improved target specificity, and utilizing nanoparticles for safer and more effective RNAi delivery are promising areas for research and development. Companies should invest in merging RNAi with other gene-editing technologies like CRISPR to expand therapeutic applications and leverage partnerships with academic and research institutions to accelerate innovation and adoption in this dynamic market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Interference Technology Market

The RNA Interference Technology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the RNA Interference Technology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Interference Technology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Interference Technology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Interference Technology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Interference Technology Market

A detailed market share analysis in the RNA Interference Technology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Interference Technology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Interference Technology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Interference Technology Market, highlighting leading vendors and their innovative profiles. These include Gradalis, Inc., Arcturus Therapeutics Holdings Inc., Merck KGaA, NeuBase Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Novartis AG, Nutcracker Therapeutics, Inc., Bioneer Corporation, Ionis Pharmaceuticals, Inc., Arbutus Biopharma Corporation, AMSBIO, Atalanta Therapeutics, Phio Pharmaceuticals Corp., Thermo Fisher Scientific Inc., Sanofi S.A., AstraZeneca PLC, Dicerna Pharmaceuticals, Inc., Sirnaomics, Inc., ProQR Therapeutics N.V., Silence Therapeutics PLC, CureVac N.V., Alnylam Pharmaceuticals, Inc., and Gotham Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the RNA Interference Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. RNA Interference Technology Market, by Type

7. RNA Interference Technology Market, by Therapeutics

8. RNA Interference Technology Market, by Application

9. Americas RNA Interference Technology Market

10. Asia-Pacific RNA Interference Technology Market

11. Europe, Middle East & Africa RNA Interference Technology Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â